Phase III DAYBREAK study found consistent safety with Zeposia in patients with relapsing forms of multiple sclerosis.
Bristol Myers Squibb (BMS) has announced positive results from the Phase III DAYBREAK study of Zeposia (ozanimod) for relapsing forms of multiple sclerosis (MS). Findings from the open-label extension trial were showcased at the ACTRIMS Forum 2024. BMS noted that Zeposia demonstrated a consistent and sustained safety and efficacy profile, stating that there is potential for the drug as a support system for managing relapsing forms of MS.1
“These DAYBREAK data continue to validate the role of Zeposia in the long-term management of relapsing forms of multiple sclerosis, with two-thirds of patients relapse-free at six years of treatment,” said study investigator Bruce Cree, MD, PhD, MAS, professor of clinical neurology, University of California San Francisco (UCSF) Weill Institute for Neurosciences, clinical research director, UCSF MS Center, in a press release. “These findings add to our confidence in Zeposia as an important treatment option for people living with the disease, highlighting its efficacy and safety over time.”
Investigators enrolled a total of 2,494 patients were administered Zeposia for approximately 61 months. The treatment showed a low annualized relapse rate of 0.098, with three- and six-month confirmed disability progression (CDP) being absent in both 82.8% and 84.8% of participants. During the DAYBREAK trial, the most frequently reported adverse events were nasopharyngitis, headache, COVID-19 infection, and upper respiratory tract infection.1
“Currently no cure exists for multiple sclerosis, but effective strategies and treatments can help slow disease progression and alleviate symptoms,” said Jonathan Sadeh, MD, MSc, SVP, head of global program leaders, immunology, cardiovascular and neuroscience development, Bristol Myers Squibb, in the release. “These DAYBREAK efficacy, safety and rebound data underscore a consistent and sustained safety and efficacy profile and add to the body of evidence supporting Zeposia’s role in the treatment armamentarium. We remain focused on advancing care and delivering meaningful innovations in neuroscience, including for the millions of people impacted by relapsing forms of multiple sclerosis.”
Last October, BMS also announced data showing that after eight years of follow-up, 76% of patients treated with Zeposia for relapsing multiple sclerosis wound up free of six-month CDP from both the DAYBREAK and RADIANCE trials. Further, Zeposia treatments reportedly resulted in low rates of progression-independent relapse activity (PIRA) and relapse-associated worsening.
“Even in the absence of relapses, people living with multiple sclerosis may have smoldering neuroinflammation, which is underlying and continuous disease activity occurring simultaneously in different areas of the brain that can start at the earliest stages of multiple sclerosis and cause an irreversible decline in cognitive function, mobility and quality of life,” said Jeffrey Cohen, MD, Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, paid consultant for Bristol Myers Squibb, in an additional press release. “Given literature has shown that 25% of people living with multiple sclerosis develop PIRA after approximately seven years, these new analyses are relevant for doctors and patients as they consider early intervention with highly effective therapies to hinder smoldering disease, an important, early driver of long-term disability and relapses, the hallmarks of disease progression.”
References
1. Bristol Myers Squibb Announces New Data from the Long-Term DAYBREAK Study Reinforcing Efficacy and Safety of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis. BMS. February 29, 2024. Accessed March 1, 2024. https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Announces-New-Data-from-the-Long-Term-DAYBREAK-Study-Reinforcing-Efficacy-and-Safety-of-Zeposia-ozanimod-in-Patients-with-Relapsing-Forms-of-Multiple-Sclerosis/default.aspx
2. Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis. BMS. October 11, 2023. Accessed March 1, 2024. https://news.bms.com/news/corporate-financial/2023/Bristol-Myers-Squibb-Presents-New-Zeposia-ozanimod-Data-on-Long-Term-Disease-Progression-and-Cognition-in-Patients-with-Relapsing-Forms-of-Multiple-Sclerosis/default.aspx
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Undertreated but High-Risk: The Hidden Health Crisis Facing 50+ Americans
May 15th 2025Leandro Boer, MD, PhD, VP, US general medicines, Amgen, explains why many high-risk Americans aged 50+ remain undertreated for cardiovascular disease, citing insurance gaps, risk misperceptions, and complex guidelines.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Novo Nordisk’s Sogroya Demonstrates Efficacy in Children with Growth Disorders
May 14th 2025Results from the Phase III REAL8 basket study found that once-weekly Sogroya was effective in children with growth disorders, including those born small for gestational age, with Noonan syndrome, or idiopathic short stature.